News

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

View more

Jul 19, 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

View more

Jul 16, 2026

AdvanCell raises $315M for targeted alpha therapy

View more

Jul 16, 2026

Actineer completes Ra-226 recycling process to support Ac-225 supply

View more

Jul 15, 2026

Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer

View more

Jul 13, 2026

New PET tracer show promise in neuroblastoma

View more

Jul 10, 2026